We are live on ! Find out more
PALI icon

Palisade Bio

4 hedge funds and large institutions have $10.4M invested in Palisade Bio in 2016 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

42% more call options, than puts

Call options by funds: $88K | Put options by funds: $62K

0% more funds holding

Funds holding: 44 (0)

0% more ownership

Funds ownership: 0%0% (0%)

31% less capital invested

Capital invested by funds: $15.1M → $10.4M (-$4.7M)

Holders
4
Holders Change
Holders Change %
0%
% of All Funds
0.11%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$88K
Puts
$62K
Net Calls
+$26K
Net Calls Change
-$31K

Top Buyers

No buyers this quarter

PALI Hedge Fund Activity: Q1 2016 in Review

4 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q1 2016, worth a combined $10.4M — down 31% from $15.1M a quarter earlier.

Fund positioning in PALI was balanced in Q1 2016: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

The largest seller was Sheaff Brock Investment Advisors, cutting an estimated $85K.

  • 4 institutional investors held Palisade Bio (PALI) as of Q1 2016, unchanged from Q4 2015.
  • Funds reported $10.4M of Palisade Bio stock for Q1 2016, down 31% quarter-over-quarter.
  • 0 funds opened new Palisade Bio positions in Q1 2016 and 0 closed out.
  • The largest Palisade Bio seller in Q1 2016 was Sheaff Brock Investment Advisors, an estimated $85K sold.

Based on aggregated 13F filings for Q1 2016.